摘要:
An ophthalmic solution containing 0.01 to 0.5 weight % of pranoprofen and 0.1 to 5.0 weight % of an organic amine, such as tromethamine or 4-(2-hydroxyethyl)-1-(2-sulfoethyl)piperazine. Such solution has a desirable stability and does not cause undue irritation when administered to eyes to treat an inflammatory disease such as keratoconjunctivitis.
摘要:
A drug support body is provided that can be used to appropriately administer a drug to the anterior segment of the eye while the production cost is reduced. A drug layer containing a drug component to be administered to an anterior segment of the eye is provided at a halfway portion in a longitudinal direction of a base plate, wherein the base plate includes a bending portion that allows the base plate to bend in a direction opposite to a surface of the base plate on which the drug layer is provided, and by bending the base plate at the bending portion, at least a portion of a surface facing the base plate of the drug layer is exposed from the base plate.
摘要:
It is intended to prepare a composition which contains polysaccharide at a high concentration and yet remains in the state of a liquid having low viscosity to thereby provide drugs, eyedrops, foods, cosmetics, toiletry products having a novel texture or function. The composition in the state of a liquid having low viscosity is obtained by heating polysaccharide at a high concentration in a water-containing liquid and then cooling under applying a shear force, which enables the provision of the above-described drugs. The composition is usable as an aqueous drug vehicle which is free from gelling due to temperature changes during storage and easily applied without pouring and/or streaming down. Eyedrops containing agar have an effect of enhancing ocular drug penetration. Eyedrops containing particulate agar maintain a low viscosity and, achieve easy instillation and impart a favorable feel in instillation.
摘要:
An aqueous ophthalmic solution containing hyaluronic acid or a salt thereof at a concentration from 0.03 to 0.5% (w/v) and propylene glycol at a concentration from 0.1 to 1.0% (w/v) comprises as a sole preservative, benzalkonium chloride at a concentration from 0.001 to 0.002% (w/v) and comprises an ionic tonicity agent at such a concentration that an osmotic pressure ratio of the ophthalmic solution becomes from 0.9 to 1.1.